MAPT and Alzheimer disease: The only hitherto published head-to-head in vivo comparison of [18F]flortaucipir with another alleged “first generation” tau PET tracer, [18F]THK5351, reported overall comparable tracer retention, with [18F]flortaucipir exhibiting slightly higher binding in Alzheimer’s disease [48].